The medication is generally used as a supportive measure alongside diet for adult patients with persistent blood fat disorders. This therapeutic domain focuses on conditions characterized by systemic imbalance.

Targeting Elevated Triglycerides and Mixed Dyslipidemia

Трайкор is commonly used to help with managing unhealthy blood fat levels in conditions such as severe hypertriglyceridemia and mixed dyslipidemia. The medication is relevant in contexts marked by increased discomfort or tension (systemic imbalance) and is used in areas where supportive symptom management is appropriate when these conditions are not controlled by lifestyle changes alone.

Achieving a More Favorable Lipid Profile

The medication is applied in addressing lipid profiles, and may contribute to better balance. It is commonly used to help with managing unhealthy blood fat levels, including triglycerides, and may assist with maintaining a sense of stability. The use of this medication provides support for managing systemic imbalance associated with these conditions.

Relevant for Easing Serious Manifestations

For patients who experience extremely high triglycerides, a key benefit is relevant for easing certain serious manifestations associated with extreme fat levels. The medication may be part of symptomatic management in situations where patients experience noticeable physiological strain, and supports the patient during difficult episodes by easing distress linked to the underlying imbalance.

---

Quick Fact: Support for Systemic Imbalance
Primary Focus	Contributes to easing symptoms related to systemic imbalance.
Context	Used in situations where symptoms persist despite lifestyle changes.

---

Трайкор (Fenofibrate) is officially established for use as an adjunctive therapy to diet in adult patients with specific lipid disorders. Eligibility for the medicine is strictly defined by regulatory authorities based on age, organ function, and specific medical conditions.

Populations That Must Not Use (Contraindicated)

The use of Трайкор is absolutely contraindicated in several patient groups, as these are formally prohibited by regulatory labeling. Contraindicated populations include patients with severe renal impairment, active liver disease (including primary biliary cirrhosis), or pre-existing gallbladder disease. It is also forbidden for patients with known hypersensitivity to fenofibrate or a history of photoallergy to other fibrates. The medicine is contraindicated for women who are nursing or breastfeeding.

Populations with Restricted or Conditional Use

• Age-Related: Use is generally not recommended for children and adolescents under 18 years of age because safety and efficacy have not been established. Use in older adults requires close assessment of renal function.
• Organ Function: Patients with mild to moderate renal impairment may use the medicine but require a dose reduction to manage potential risk. Use in pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus.

Interactions with other medicines and products

Fenofibrate, the active ingredient in TRICOR, has documented interaction patterns with several medicinal product categories as defined by regulatory authorities.

---

Documented Pharmacodynamic Interactions

Co-administration with HMG-CoA Reductase Inhibitors (Statins) or Colchicine creates a pharmacodynamic risk by increasing the likelihood of developing myopathy and rhabdomyolysis. This risk is heightened in specific populations, including geriatric patients and those with renal impairment, diabetes, or hypothyroidism, as noted in official prescribing information.

Exposure and Timing Constraints

Fenofibrate enhances the anti-coagulant effect of Coumarin Anticoagulants (e.g., Warfarin), which prolongs the Prothrombin Time (PT)/INR. When these medicines are co-administered, close monitoring of coagulation is expected. Furthermore, a timing-based restriction applies to Bile-Acid Binding Resins, which must be taken at least one hour before or four to six hours after fenofibrate to prevent the resin from impeding fenofibrate absorption. Fenofibric acid is also a mild-to-moderate inhibitor of CYP2C9, potentially altering the exposure of other drugs metabolized by this pathway.

How Трайкор Works: Mechanism of Action

The drug's mechanism involves the activation of key fat-regulating pathways, resulting in physiological modulation across three core domains. The primary interaction occurs as a selective agonist of the Peroxisome Proliferator-Activated Receptor alpha (PPARalpha), a nuclear receptor that regulates gene expression in tissues like the liver.

Activation of PPARalpha initiates a genetic cascade that alters the production of proteins essential for processing lipids. This action promotes the breakdown of circulating fat by increasing the activity of the enzyme lipoprotein lipase (LPL). This enhancement leads to the removal and destruction of triglyceride-rich particles, such as VLDL, from the bloodstream, resulting in a reduction in circulating triglyceride levels.

Furthermore, by modulating gene expression, the drug alters the structural components of lipoproteins. It increases the production of proteins found in High-Density Lipoprotein (HDL) cholesterol, resulting in an increase in circulating HDL levels and inducing a shift toward a larger, less dense Low-Density Lipoprotein (LDL) particle profile.

Administration Scope

The administration of fenofibrate (Трайкор) is strictly limited to the oral route using the available tablet or capsule forms. The regimen is standardized to a once-daily schedule. The tablets must be swallowed whole and should not be crushed, broken, or chewed. This medicine may be administered with or without food.

---

Official Dosing and Monitoring

The maximum recommended daily dose for the tablets is 145 mg. For primary hyperlipidemia or mixed dyslipidemia, the standard dose is 145 mg daily. When treating severe hypertriglyceridemia, the initial daily dose may range from 48 mg to 145 mg.

Dosage adjustments are guided by lipid determinations reviewed at 4- to 8-week intervals. Treatment should be discontinued if an adequate response is not achieved after two months of treatment at the maximum dose.

---

Special Conditions and Adjustments

• Missed Dose: If a dose is missed, it is advised to skip the missed dose and resume the regular schedule.
• Timing Constraint: The medicine must be taken at least 1 hour before or 4 to 6 hours after the administration of a bile acid binding resin.
• Renal Impairment: For patients with mild to moderate renal impairment, the initial dose is reduced to 48 mg once daily.
• Pediatric Use: Use is generally not recommended for patients under 18 years of age.

Research Evidence / Overview of Studies for Трайкор

Evidence for use in Primary Hypercholesterolemia and Mixed Dyslipidemia

Research has explored the effects of Трайкор in adults with lipid imbalances, primarily utilizing Randomized Controlled Trials (RCTs) and systematic reviews. Researchers examined changes in specific lipid biomarkers, such as LDL-C and triglycerides, over various periods. When exploring the longer-term cardiovascular outcomes (such as heart attack or stroke), the reported patterns often showed limited differentiation from control groups across the overall populations that were observed. It is not yet clear whether the recorded changes in lipid biomarkers consistently correspond to a defined pattern of long-term cardiovascular outcomes.

---

Evidence for use in Severe Hypertriglyceridemia

Studies was evaluated in individuals with very high levels of triglycerides, primarily using Phase III RCTs. Research examined the magnitude of change in plasma triglyceride concentrations. The data show patterns related to the triglyceride measurements recorded in these specific, high-risk populations from the start of the study. However, this evidence primarily contributes to understanding biomarker patterns, and research exploring the direct link to a reduction in clinical outcomes, such as acute pancreatitis, remains limited.

---

Evidence for use in Diabetic Retinopathy

The research was evaluated in patients with Type 2 Diabetes, derived from large-scale, long-term RCTs. Studies monitored outcomes related to the rate of progression of diabetic retinopathy and the need for specific laser treatments. The findings describe patterns where the number of patients requiring laser treatment, and the progression of the retinopathy itself, was observed between the group receiving the drug and the control group in the context of the study. The full understanding of the mechanistic pathways by which these changes were observed is not fully established.

---

What is Still Uncertain About Трайкор

Despite numerous studies, long-term effects are not fully established for all outcomes. Comparative evidence is lacking in some areas, and the findings regarding cardiovascular events were often mixed. Data remain insufficient for certain critical groups, such as pregnant women or children/adolescents, and the data for certain groups remain insufficient including those with significant chronic kidney disease. These results apply only to the populations studied.

Common questions about Трайкор (FAQ)

---

Q: How quickly should I expect Трайкор to start working?

According to official product information, the active substance reaches its highest concentration in the blood within 6 to 8 hours after administration. However, the full therapeutic effect is assessed by a healthcare provider through blood tests (lipid determinations), which are generally reviewed at 4- to 8-week intervals to guide the evaluation of treatment response.

---

Q: Can Трайкор interact with blood thinners?

Regulatory documents state that Fenofibrate can enhance the anti-coagulant effect of certain blood thinners, specifically those known as Coumarin Anticoagulants (such as Warfarin). Official guidelines note that close monitoring of coagulation tests (PT/INR) is expected when these medicines are taken together.

---

Q: What kind of diet is best when taking Трайкор?

Трайкор is officially established for use as an adjunctive therapy to diet. Regulatory information indicates that controlling blood fat levels involves following an appropriate diet, physical exercise, and weight management, particularly in obese patients.

---

Q: How long after starting Трайкор do follow-up blood tests happen?

Official guidelines state that blood lipid levels should be determined periodically during initial therapy. These determinations are typically reviewed by a healthcare provider at 4- to 8-week intervals to guide any potential dosage adjustments.

---

Q: What research supports the use of Трайкор for heart health?

Studies have examined the medicine’s effects on various blood fats (lipid biomarkers) and its role in slowing the progression of diabetic retinopathy in people with Type 2 Diabetes. However, official documents indicate that Fenofibrate did not reduce coronary heart disease morbidity or mortality in two large clinical trials of diabetic patients.

---

Q: Do studies show Трайкор prevents heart attacks?

Official documents explicitly state that Fenofibrate did not reduce cardiovascular disease morbidity or mortality (including heart attack or stroke) in two large, randomized controlled trials of patients who had Type 2 Diabetes mellitus. The primary research focus has centered on changing blood fat levels and certain diabetes-related outcomes.

---

Q: Is Трайкор considered a 'statin' medication?

No, Трайкор is not a statin. It is classified as a fibric acid derivative, belonging to the fibrate class of medicines. Fibrates work by regulating the breakdown of fats in the body, which is a different mechanism from how statin medicines inhibit cholesterol production.

---

Q: Does Трайкор have a generic version available?

The active ingredient in Трайкор is fenofibrate. Official regulatory information confirms that fenofibrate is available as a generic medicine in various formulations.

---

Q: Are there any common foods or drinks that interact with Трайкор?

Official patient information for fenofibrate products notes that grapefruit juice may be avoided when taking this medicine. Separately, administration instructions state the tablets can generally be taken with or without food.

---

Q: Does taking Трайкор affect blood sugar levels?

While the medicine is not used to treat blood sugar levels, clinical trials evaluating the drug's effects have often included people with Type 2 Diabetes mellitus. The official guidelines recommend comprehensive patient management that includes monitoring for multiple health factors.

---

Q: Is it common to feel tired when first starting Трайкор?

In official safety reporting, generalized fatigue or unusual weakness (asthenia) has been noted. It is important to know that unusual tiredness or muscle weakness can also be a symptom associated with rare but serious effects like muscle or liver problems, which official warnings advise consulting a healthcare provider about.

---

Q: Are there any known side effects on mood or sleep from Трайкор?

Official safety data lists Insomnia (difficulty sleeping) as a common side effect of the medicine. Other psychiatric disorders, such as anxiety and depression, have also been noted in official post-marketing reports with a frequency that is not fully established.

---

Q: Is Трайкор a medication that needs to be refrigerated?

No, this medicine does not require refrigeration. Regulatory storage conditions specify that it must be kept at Controlled Room Temperature (20 C to 25 C). It must be protected from freezing, excessive heat, moisture, and light.

---

Q: Can I drink alcohol while taking Трайкор?

Official patient information notes that the consumption of large quantities of alcohol may be avoided while using this medicine. This caution is advised because high alcohol intake may increase the potential risk of liver problems associated with fenofibrate.

---

Q: What are the main things to avoid while taking Трайкор?

Official documents identify several things to avoid. This includes taking the medicine with certain bile-acid resins without proper timing separation, large amounts of alcohol, and for certain patient populations, co-administration with some statin medications due to increased risk of muscle issues.

---

Q: Is it normal to see changes in urine color when taking Трайкор?

Official adverse event reporting lists dark urine as a rare side effect. Dark urine is also a potential sign of a serious, rare muscle problem (rhabdomyolysis) that official warnings advise consulting a healthcare provider about.

---

Q: Is it safe to drive or operate machinery while taking Трайкор?

Official patient information notes that caution is advised when driving or operating machinery. This is advised because official safety data lists Dizziness as a common side effect.

---

Q: What if I'm having surgery; should I stop taking Трайкор?

Official warnings advise that the medicine should be temporarily discontinued in patients experiencing an acute or serious condition that carries a high risk of severe muscle breakdown (rhabdomyolysis), which can include major surgery. The decision to temporarily discontinue the medicine in such cases is determined by a healthcare provider.

---

Q: Does Трайкор work better at certain times of the day?

The administration regimen is standardized to a once-daily schedule. The medicine can generally be taken at any time of day, and it may be taken with or without food depending on the specific formulation.

---

Q: Why do official documents warn against taking Трайкор with grapefruit juice?

Regulatory sources advise that grapefruit juice should be avoided when taking this medicine. This caution is issued because grapefruit juice may potentially alter how the drug is processed by the body, as described in official labeling.

---

Q: Is it normal to feel a bit dizzy when first starting the medication?

Official adverse event reporting lists Dizziness as a common side effect of this medicine. Because dizziness is listed, official patient information advises caution when driving or operating machinery.

The storage and disposal of Трайкор (fenofibrate) must adhere to the conditions specified in official regulatory labeling to maintain product stability.

Storage Conditions

Requirement	Classification
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.
Protection	Keep from freezing, excess heat, excess moisture, and light.
Container	Must be stored in the original container and kept tightly closed.
Child Safety	Must be kept out of the reach of children.

Disposal Instructions

When disposing of unused or expired Trісor, official guidelines recommend using a drug take-back program when available. The medicine is not on the list for disposal by flushing down the toilet or sink. If a take-back program is unavailable, the product must be removed from its container, mixed with an undesirable substance (such as dirt or coffee grounds), and sealed in a container or bag before being placed in household trash.